We first examined the association between the number of Meflin+ CAFs and the outcomes of patients with unresectable clear cell renal cell carcinoma (ccRCC) and UC, who were treated with either conventional chemotherapy (Supplementary Tables S1 and S2) or ICB therapy (Table 1 and Supplementary Table S3). This evidence concerns the gene ISLR and nonpapillary renal cell carcinoma.